Participant Registration of 2020 CBIIC is Online

2020-08-24 14:43


2020 China BioMed Innovation and Investment Conference (2020 CBIIC) will be held on September 27-29 in Suzhou Industrial Park. As an annual grand conference to promote the communication between pharmaceutical industry and investment industry, CBIIC was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA).                                             



The Participant Registration is online! Looking forward to your participation.




Scan the QR Code to register

Introduction of CBIIC

Established by PhIRDA in 2016, CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX), Chinese Hospital Association (CHA) and Research and Development International (RDI) from 2016 to 2019 as an annual grand conference to promote the communication between pharmaceutical industry and investment industry.


I.     Supported by National Authorities and Highly Recognized

2020 CBIIC will be co-hosted by PhIRDA, CAMDI, HKEX and iMeta Health Information Consulting Co., Ltd., supported by Chinese Academy of Medical Sciences, Southern Medicine Economic Research Institute, Suzhou Industrial Park, Zhongguancun Private Equity & Venture Capital Association (ZVCA), Hong Kong Bio-Med Innotech Association (HKBMIA), Institute for Biotechnology and Medicine Industry (IBMI), Japan Pharmaceutical Manufacturers Association (JPMA), BioCentury and China Association for Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC). Top leading international institutions including Springer Nature and J.P. Morgan has supported previous CBIIC as well. 2020 CBIIC covers the latest analysis of the industry policy, presentation of the cutting-edge innovation project, hot topics of R&D home and abroad and trends of investment. By the end of 2019, CBIIC has attracted over 10,000 participants, 2,100 domestic and foreign pharmaceutical enterprises and 1,500 investment institutions, and 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in this events, receiving extensive attention and highly recognized from pharmaceutical industry and investment home and abroad.                                            

II.   Fascinating and excellent parallel sessions based on Industry Demand and Hot Spot of R&D and Investment

Under the background of biopharmaceutical industry being included into the national central pillar industries, 2020 CBIIC will remain true to its original aspiration to promote the linkage between social capital and pharmaceutical innovation, focus on China’s latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. 2020 CBIIC will set up fascinating and excellent parallel sessions covering biopharmaceutical, immunotherapy, AI for drug design, Big Data + WIT MED and innovative medical devices, meeting diversified needs of participants.

III.  Release of the Selection of Post COVID-19 Biopharmaceutical Innovative City with Most Investment Value in China

Initiated by PhIRDA and RDPAC and collaborated with IQVIA as project research and service partner, Selection of Post COVID-19 Biopharmaceutical Innovative City with Most Investment Value in China (hereinafter referred to as Selection) will be launched. Based on the principles of transparent, traceable and public, combining with the opinions of independent experts, taking cities as basic units, the three parties will build China's biopharmaceutical industry innovation capability evaluation system. The results of the Selection will be released on the 2020 CBIIC to help the government and institution explore and judge the direction of urban pharmaceutical industry development and facilitate the investors to discover the most valuable pharmaceutical ecosystem.  

IV.  One-on-One Partnering System for Close Business Communication between Participants

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2020 CBIIC will continue to build a better and more diverse platform for project presentation and communication. 2020 CBIIC will keep providing One-on-One partnering service for participants and roadshow speakers to seek potential opportunities for further collaboration.